Strong Market Presence Hovione's extensive global footprint with four FDA-inspected sites in the USA, Portugal, Ireland, and China positions it as a key player in the pharmaceutical manufacturing sector, offering ample opportunities to collaborate on international projects.

Financial Robustness With a reported revenue of approximately 10 billion dollars, Hovione demonstrates significant financial strength, enabling investment in expanding capacities and innovative solutions to meet growing client demands.

Innovation & Sustainability As the first chemical/pharmaceutical company to become a Certified B Corp and an active participant in industry quality initiatives, Hovione emphasizes sustainability and high-quality standards, making it an attractive partner for clients focused on responsible development.

Recent Investments A recent $100 million investment round specifically allocated to its New Jersey site indicates Hovione’s commitment to expanding its manufacturing and development capabilities, opening opportunities for suppliers and technology providers to engage.

Industry Engagement Regular participation in major industry events such as CPHI China, INTERPHEX Tokyo, and OPR&D Conferences showcases Hovione’s active role in shaping market trends and fostering partnerships, providing sales teams with strategic avenues to connect with decision-makers.